

**PRODUCT DESCRIPTION**

AggRecetin® is lyophilized Ristocetin A Sulfate, a substance of unknown chemical structure which is isolated from *Nocardia lurida*. AggRecetin contains in excess of 90% Ristocetin A.

**INTENDED USE**

AggRecetin is for use in the detection of von Willebrand Syndrome, the quantitation of von Willebrand factor, and the identification of Bernard-Soulier Syndrome.

**PRINCIPLE**

In the presence of the von Willebrand factor, AggRecetin induces agglutination of platelets in platelet rich plasma or standardized fixed platelet suspensions.<sup>11-13</sup>

**PRECAUTIONS**

AggRecetin is for *IN-VITRO* DIAGNOSTIC USE ONLY AND NOT FOR INJECTION OR INGESTION.

**MATERIALS PROVIDED**

AggRecetin is provided in standard and variable final (in test) concentrations. (See reconstitution.) Store at room temperature prior to reconstitution.

1. 1.0-1.5 mg/mL 15 mg AggRecetin and 2.0mL diluent (0.85% Saline)
2. 100 mg Bulk AggRecetin only
3. 1 gram Bulk AggRecetin only

**MATERIALS REQUIRED BUT NOT PROVIDED**

1. Platelet Aggregometer
2. Pipettors (0.5mL, 0.45mL, 0.5mL volumes)
3. Disposable Stir Bars
4. Aggregometer cuvettes

**INSTRUMENTATION**

AggRecetin will perform as described when used on most optical platelet aggregometers<sup>1</sup>. Follow the manufacturer's instructions for operating the aggregometer in use.

**SPECIMEN COLLECTION AND PREPARATION OF TEST SAMPLE**

Refer to the current NCCLS Approved Guideline H21 A2 for detailed specimen collection and sample preparation instructions.<sup>6</sup>

**1. PATIENT PREPARATION:**

Patients should refrain from taking aspirin or medications containing aspirin, other medications and dietary supplements known to affect platelet function for 7 - 10 days prior to specimen collection. Patients should fast and avoid fatty foods and dairy products for 12 hours prior to specimen collection.<sup>6</sup>

**2. SPECIMEN COLLECTION:**

Blood collection should be performed with care to avoid stasis, hemolysis, contamination by tissue fluids, or exposure to glass. Keep specimens at room temperature.<sup>8</sup>

Each of the following can cause test results to be inaccurate; and affected specimens should be rejected: hemolysis, RBC contamination, lipemia, chylous, icterus, thrombocytopenia (<75,000/mm<sup>3</sup>) clots in specimen, and hypofibrinogenemia. Reuse of disposable items may result in inaccurate test results.

Observe standard precautions throughout the specimen collection, sample preparation and analytical processes.<sup>2,3</sup> Dispose of sharps and biological waste in accordance with laboratory policy.

**Syringe Technique (recommended)<sup>8</sup>**

- a. Use a butterfly needle for the venipuncture
- b. Draw 9.0mL of blood into a plastic syringe. Avoid excess suction.
- c. Remove the needle from the syringe and immediately and gently dispense the blood into a plastic [polypropylene]<sup>4</sup> tube containing 1.0mL of 0.11M Sodium Citrate anti-coagulant. The ratio of blood to anti-coagulant must be 9 parts of blood to 1 part anti-coagulant.<sup>5</sup>
- d. Cover and invert 4-5 times gently to mix.
- e. Maintain at room temperature (15° to 28°C)

NOTE: When the patient's hematocrit is < 30% or > 55%, the blood to anti-coagulant volumes must be adjusted.<sup>4</sup>

**Evacuated Collection Tube Technique**

1. Use a butterfly needle for the venipuncture
2. Draw blood using (plastic) tubes containing 0.11M Sodium Citrate anti-coagulant
3. Gently invert 4-5 times to mix

NOTE: When using plastic vacuum collection tubes, make sure the citrate anti-coagulant is 0.11M by checking the label. Colored tops do not vary with differing citrate concentrations. Follow the manufacturer's instructions for specimen collection.

**RECONSTITUTION**

NOTE: Reagents must be at room temperature (15° to 28°C) prior to reconstitution. Stored reagent must be brought to room temperature prior to use.

Catalog No. 100970

1. 1.0-1.5mg/mL Final/10-15mg/mL Working
  - a. Refer to dilution chart below for the desired concentration of AggRecetin and required diluent volume.
  - b. Add selected volume of diluent to the glass vial of AggRecetin.
  - c. Invert gently to mix. Allow to stand until completely dissolved.

Catalog No. 101241 (100 mg) or 107484 (1 gram)

1. Bulk
  - a. Place 15mg of AggRecetin in a 10mL glass vial.
  - b. Reconstitute with 0.85% Saline
  - c. Refer to the Dilution Chart for the desired concentration of AggRecetin and required diluent volume.
  - d. Add selected volume of diluent to the vial of AggRecetin.
  - e. Invert gently to mix for 30 minutes. A specimen rocker can be used.

**DILUTION CHART**

All Final concentrations are based upon 0.05mL of AggRecetin added to 0.45mL of platelet rich plasma.

To 15mg AggRecetin Add Diluent In The Amount Of	Working Concentration (as reconstituted)	Desired AggRecetin Final Concentration (in test)
1.00 mL	15 mg/mL	1.5 mg/mL
1.07 mL	14 mg/mL	1.4 mg/mL
1.15 mL	13 mg/mL	1.3 mg/mL
1.25 mL	12 mg/mL	1.2 mg/mL
1.36 mL	11 mg/mL	1.1 mg/mL
1.50 mL	10 mg/mL	1.0 mg/mL

**REAGENT STORAGE**

The reconstituted AggRecetin is stable for 7 days when stored at 2° - 8°C in its original tightly sealed container. For long term storage, freeze reconstituted AggRecetin at -20°C for up to 8 weeks. Once thawed use within 8 hours. Reagent needs to be gently inverted for 30 minutes while reaching room temperature.

**TEST PROCEDURE**

Testing must be completed within 3 hours of specimen collection.<sup>8</sup>

1. Place a stir bar in each cuvette
2. Prepare an aggregometer blank by pipetting 0.5mL platelet poor plasma into a cuvette.
3. Pipette 0.45mL platelet rich plasma into a second cuvette. Incubate at 37°C for 3 minutes.
4. Set, if required, the 0% and 100% baselines according to the manufacturer's instructions for the aggregometer in use.
5. Add 0.05mL AggRecetin directly into the platelet rich plasma. Do not allow reagent to run down the wall of the cuvette.
6. Allow the aggregation pattern to generate for 5 minutes.

**QUALITY CONTROL**

Laboratories should follow generally accepted quality control practices when assay specific proficiency testing is not available.

To assure proper instrument operation and reagent performance, a control specimen should be evaluated each day that tests are performed. The control specimen should be prepared in the same manner as the test specimen. For qualitative platelet aggregation studies, the control should consist of fresh platelet rich plasma collected from a (specified and qualified) normal donor who has not ingested aspirin containing compounds within 10 days of testing and has a history of normal platelet function.

## EXPECTED VALUES

Expected ranges for each reagent at various concentrations used to induce platelet aggregation should be established by each laboratory, see Table 2.<sup>4,8,9,10</sup>

Table 2

### TYPICAL PLATELET AGGREGATION RESPONSES FOR NORMAL DONORS @ 250,000 PLATELETS/mm<sup>3</sup> [total aggregation at 5 minutes]

	AggRecetin (Ristocetin Sulfate)	AggRecetin
Final Conc.	1.5 mg/mL	1.0 mg/mL
Lag Phase [sec]	0	-
Primary Slope	32-63	15-34
Total Aggregation (%@5min)	68-106	55-80
Biphasic Aggregation	Maybe at lower concentrations	Variable
Other	---	Normal donors may vary

## LIMITATIONS

A detailed patient history is required for accurate test interpretation. Patients should be questioned about the recent ingestion of any medication, because a number of prescription and nonprescription drugs may interfere with platelet aggregation. Substances such as caffeine, tobacco, herbal extracts (or supplements) and alcohol may affect results.<sup>7,8</sup>

## PERFORMANCE CHARACTERISTICS

Studies have shown that this product will perform as described prior to its expiration date when procedural and storage directions are followed.

### Linearity:

Platelet aggregation induced by common agonists (Ristocetin A) is a nonlinear test system for the following parameters: Lag Phase, Primary Slope, Secondary Slope, biphasic response and disaggregation. The non-linearity is caused by many factors such as the reaction chemistry and instrumentation. Platelet aggregation measures a response rate or activity that is not a quantitative measure of the reactants or their concentration.

## ACCURACY, PRECISION AND REPRODUCIBILITY

### Accuracy

In platelet aggregation, accuracy is a relative parameter and is dependent on the test system.

### Precision and Reproducibility

The limitations of platelet aggregation make it difficult to provide typical precision or reproducibility ranges. However, there is an experienced based consensus for these parameters (see below). Each laboratory must establish its own limits for test acceptability.

Test to Test Reproducibility:	better than $\pm$ 7.5%
Instrument to Instrument Reproducibility:	better than $\pm$ 15%
Reagent Lot to Lot Variation:	better than $\pm$ 10.5%
Laboratory to Laboratory (same test system):	better than $\pm$ 12.5%

Note: When comparing Ristocetin Cofactor to von Willebrand Factor Antigen for diagnostic interpretation, note that patients with Type O blood have significantly lower plasma levels of von Willebrand Factor Antigen than other blood types.<sup>9</sup>

## REFERENCES

1. Born, GVR and Cross, MJ. The Aggregation of Blood Platelets. J. Physiol [London] 168:178, 1963.
2. Centers for Disease Control and Prevention. Guidelines for Isolation Precautions in Hospitals. Centers for Disease Control and Prevention. 1996; Vol 17; 1:53 - 80.
3. National Committee for Clinical Laboratory Standards. NCCLS: Protection of Laboratory Workers from Occupationally Acquired Infections: Approved Guideline. NCCLS document M29. Wayne, PA
4. McCabe-White, M and Jennings, LK. Platelet protocols: Research and Clinical Laboratory Procedure. Academic Press. London. 1999, p 35.
5. Newhouse, P and Clark, C. The Variability of Platelet Aggregation., in Triplet, DA, ed. Platelet Function: Laboratory Evaluation and Clinical Application. ASCP. Chicago. 1978. p 69.
6. National Committee for Clinical Laboratory Standards. NCCLS Collection, Transport and Processing of Blood Specimens Approved Guideline- Second Edition. NCCLS Document H 18-A2. Wayne, PA
7. Weiss HJ: Aspirin and platelets in drugs and hematologic reactions. Dimitrov and Nodine (eds.). Grune and Stratton, New York, 1974.
8. Triplett DA, Harms CS, Newhouse P, Clark C: Platelet Function. Laboratory Evaluation and Clinical Application. ASCP, 1978.
9. Day HJ, Holmsen H: Laboratory tests of platelet function. Ann Clin Lab Sci, 2:63, 1972.
10. Owen CA, Bowie EJW, Thompson JH: The diagnosis of bleeding disorder. Little, Brown and Co., 1975.
11. Howard MA, Firkin BG: Ristocetin - A new tool in the investigation of platelet aggregation. Throm Diath Heimorrh, 26:362, 1971.
12. Allain JP, Cooper HA, Wagner RH, et al: Platelets fixed with paraformaldehyde: A new reagent for the assay of von Willebrand factor. J. Lab Clin Med, 85:318, 1975.
13. Brinkhous KM, Graham JE, Cooper HA, Allain JP, Wagner RH: Assay of von Willebrand factor in von Willebrand disease and hemophilia. Use of a macroscopic platelet aggregation test, Throm Res 6:267, 1975.

For a complete list of available products please go to our web site [www.biodatacorp.com](http://www.biodatacorp.com) or contact customer service below.

THIS PRODUCT IS WARRANTED TO PERFORM AS DESCRIBED IN THE LABELING AND IN THE LITERATURE OF BIO/DATA CORPORATION AND BIO/DATA CORPORATION DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY OTHER PURPOSE AND IN NO EVENT SHALL BIO/DATA CORPORATION BE LIABLE FOR ANY CONSEQUENTIAL DAMAGES ARISING OUT OF THE AFORESAID EXPRESSED WARRANTY.



155 Gibraltar Road, Horsham, PA 19044 U.S.A.  
(800) 257-3282 U.S.A. (215) 441-4000 Worldwide  
(215) 443-8820 Fax Worldwide  
E-mail: [customer.service@biodatacorp.com](mailto:customer.service@biodatacorp.com)  
Internet: [www.biodatacorp.com](http://www.biodatacorp.com)  
An ISO 13485:2003 Registered Company



EMERGO EUROPE  
Prinsessegracht 20  
2514 AP The Hague  
The Netherlands

